live news from africa (2023)

Osaka, Japan - Saturday, July 10, 2021[Przelew AETOS]

(business wire) --Takeda Pharmaceutical Co., Ltd.(TSE: 4502 / NYSE: TAK)("Takeda") today announced the results of two final phase 3 analyzes of the Hereditary Angioedema Long-Term Prevention (HELP) studyAn open-label (OLE) extension evaluating the long-term safety (primary endpoint) and efficacy of TAKHZYRO®(lanadelumab) 300 mg every two weeks for up to 2.5 years. In the first analysis, the mean (minimum, maximum) reduction in Aggression Index was 87.4% (-100; 852.8) and the median reduction was 97.7% compared to baseline observed in the study population (N=212) %, the mean (standard deviation) duration of treatment patients received was 29.6 (8.2) months.1At steady-state, from day 70 to the end of the treatment period, aggression indices further decreased to an average of 92.4% and a median reduction to 98.2%.2,3Another analysis further showed that TAKHZYRO was a well-tolerated drug that prevented HAE episodes in specific subgroups of HAE patients and disease characteristics over an extended 132-week treatment period.3The data will be presented at the Mixed Congress of European Allergy and Clinical Immunology (EAACI) 2021 in Krakow, Poland and Madrid, Spain.

"Hereditary angioedema is a lifelong condition, and research has shown that the fear of another attack can limit a patient's lifestyle," said Markus Magerl, MD, Department of Dermatology, Venereology and Allergology, Charité Medical University Berlin, Germany, said the professor. "The effectiveness of TAKHZYRO in the long-term prevention of HAE episodes will be an important consideration for patients and physicians when developing treatment plans for patients aimed at reducing the number of HAE episodes."

The original Phase 3 HELP study, conducted in 125 patients aged 12 years and over for 26 weeks, is the largest randomized controlled trial of HAE prevention to date and the longest active treatment to date.4The HELP OLE study was designed to evaluate the long-term safety (primary endpoint) and efficacy of TAKHZYRO for up to 2.5 years. Full results are based on data collected between May 2016 and October 2019 and include 109 patients with relapse initially assessed in the HELP study and 103 eligible non-transfer patients who did not participate in the initial study but experienced at least one HAE . The patient has had seizures in the last 12 weeks.1

Seizure-Free Status During Stable Lanadelumab Treatment in Patients with Hereditary Angioedema: Results of the HELP Open-Label Extension Study (ePoster Presentation: Abstract #342)

The results of the HELP OLE study showed that TAKHZYRO was consistently effective in preventing HAE attacks by reducing the frequency of attacks over a treatment period of up to 132 weeks. TAKHZYRO has a half-life of approximately 14 days and is expected to reach steady state in approximately 70 days. The steady-state seizure-free analysis of the HELP OLE study showed that the efficacy of TAKHZYRO 300 mg subcutaneously every two weeks in rolling patients was consistent with the preliminary results of the HELP study.2

Compared to the baseline observed in the study population (N=212), the mean (minimal, maximal) reduction in aggression index was 87.4% (-100; 852.8) and the median reduction was 97.7% (98.0 % reversed, 96.9% irreversible).1,2Steady-state attack rate is further reduced to an average of 92.4% (-100, 0.44), which includes 92.7% rolls (-100, -40.9) and 91.9% no-rolls (-100 , 0.44), with a median number reduced by 98.2% (98.4% knocked down, 97.3% not knocked down). Within the first six months of treatment after day 70 of the steady-state phase, 58.6% of patients (n=119) were seizure-free, 54.7% relapsed, and 62.9% were seizure-free. The longest duration of seizure-free periods after day 70 was ≥ 6 months in 83.7% and ≥ 12 months in 70%. The median and longest seizure-free periods at steady-state were 14.8 and 18.6 months, respectively, with a maximum seizure-free period of more than 12 months in 70.0% of patients (n=142).2

Long-term prevention of exacerbations in a subgroup of patients with hereditary angioedema (HAE) with lanadelumab: final results of the open-label extension study HELP (oral presentation: abstract #392)

In the OLE analysis of the follow-up HELP study, treatment with TAKHZYRO 300 mg every two weeks was well tolerated and effective over the extended treatment period in reducing HAE type, seizure quality index, history of long-term prophylaxis use, and baseline morbidity.3

The safety profile of TAKHZYRO was comparable across all subgroups evaluated, with 54.7% of patients (n=116) experiencing treatment-related TEAEs, most commonly injection site pain.3

"For over a decade, we've been listening to the HAE community to better understand the need for long-term, targeted preventive therapies and dedicating our resources to developing treatment options," said Neil Inhaber, M.D., vice president, Global Medical, Takeda (Takeda) Director of HAE and Transplantation. "These analyzes further confirm that TAKHZYRO can play an important role in the lives of HAE patients."

(Video) Africanews english Live

O TAKHZYRO® (lanadelumab)

TAKHZYRO® (lanadelumab) is indicated for the routine prophylaxis of recurrent HAE episodes in patients 12 years of age and older. TAKHZYRO is a fully human monoclonal antibody that specifically binds to plasma kallikrein and reduces its activity. TAKHZYRO is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. 9

TAKHZYRO is for subcutaneous use and has a half-life of approximately two weeks in HAE patients. TAKHZYRO is indicated for self-administration or administration by a healthcare professional only after training by a healthcare professional. 9

TAKHZYRO is not indicated for the treatment of acute episodes of HAE. 9

TAKHZYRO is available in 300 mg vials or pre-filled syringes under regional marketing authorisation. Please check your local prescribing information for more information.

TAKHZYRO European Safety Information

Please refer to the Summary of Product Characteristics (SmPC) of TAKHZYRO before prescribing.

TAKHZYRO treatment should be initiated under the supervision of a physician experienced in the management of patients with hereditary angioedema (HAE). TAKHZYRO should only be self-administered or administered by a caregiver after training by a healthcare professional in the subcutaneous injection technique. 9


Hypersensitivity to the active substance or to any of the excipients. 9

Warnings and measures

(Video) South Africa energy crisis could lose ANC government’s majority - BBC News

Traceability: To improve the traceability of biopharmaceutical products, names and batch numbers of managed products should be clearly recorded. 9

Hypersensitivity reactions have been observed. If severe hypersensitivity reactions occur, TAKHZYRO should be discontinued immediately and appropriate therapy initiated. 9

General: TAKHZYRO is not indicated for the treatment of acute episodes of HAE. In the event of a breakthrough HAE episode, individualized treatment with approved rescue medications should be started. There are no clinical data available on the use of lanadelumab in HAE patients with normal C1-INH activity. 9

Effects on coagulation test results: Due to the interaction of lanadelumab with the aPTT assay, lanadelumab may increase activated partial thromboplastin time (aPTT). The reagent used in the aPTT laboratory test initiates internal coagulation by activating plasma kallikrein in the contact system. Inhibition of plasma kallikrein by lanadelumab increases aPTT in this assay. In patients treated with TAKHZYRO, no increase in APTT was associated with abnormal bleeding adverse events. The international normalized ratio (INR) did not differ between the treatment groups. 9

Sodium content: This medicine contains less than 1 mmol (23 mg) sodium per vial, that is to say essentially sodium free. 9


No specific drug interaction studies have been performed. Based on the properties of lanadelumab, no pharmacokinetic interactions with co-administered drugs are expected. 9

As expected, based on the mechanism of action (MOA) of lanadelumab and C1 esterase inhibitors, co-administration of the rescue drug C1 esterase inhibitor had an additive effect on lanadelumab-cHMWK response. 9


Treatment with lanadelumab was associated with treatment-emergent anti-drug antibodies (ADA) in 11.9% (10/84) of patients. All antibody titers were low. ADA reactions were transient in 20% (2/10) of ADA positive patients. 2.4% (2/84) of patients treated with lanadelumab tested positive for neutralizing antibodies. 9

The development of ADA, including neutralizing antibodies to TAKHZYRO, does not appear to adversely affect the pharmacokinetic (PK) and pharmacodynamic (PD) profiles or clinical response. 9

(Video) IST-Africa 2023 Conference: Exploring Blockchain, Digital Payments, and Mobile Finance | Part 1

Side effects

The most common adverse reactions (52.4%) associated with TAKHZYRO were injection site reactions (ISRs), including injection site pain, injection site erythema, and injection site bruising. Of these ISRs, 97% were mild, 90% resolved within 1 day of onset, with a median duration of 6 minutes. 9

Hypersensitivity reactions (mild to moderate itching, tongue discomfort and tingling) have been observed (1.2%)

very often

(incidence ≥ 1/10):

Injection site reactions*


(≥1/100 do <1/10):

Hypersensitivity**, dizziness, maculopapular rash, myalgia, alanine aminotransferase increased, aspartate aminotransferase increased.

*Injection site reactions include: pain, erythema, bruising, discomfort, hematoma, haemorrhage, itching, swelling, induration, paraesthesia, reaction, fever, edema and rash.

** Hypersensitivity reactions include: itching, discomfort and tingling of the tongue.

(Video) Rand reaction to latest news on BRICS Summit and Putin: Peter Attard Montalto

The Summary of EU Product Characteristics is available at

Full US prescribing information, including approved indications and important safety information, can be found at

O firmie Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TOKYO: 4502 / NYSE: TAK) is a global, values-driven, research and development-driven biopharmaceutical leader based in Japan, dedicated to discovering and delivering life-changing therapies in the spirit of what we do for our patients, our people and planet. Takeda focuses its research and development efforts on four therapeutic areas: oncology, rare genetics and hematology, neurology and gastroenterology (GI). We also make targeted investments in research and development for plasma-derived drugs and vaccines. We focus on developing highly innovative medicines that help transform people's lives by pushing the boundaries of new therapeutic options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees work to improve the quality of life for patients and work with our medical partners in approximately 80 countries. For more information, please visit

important reminder

For the purposes of this notice, "press release" means this document, any oral presentations, any Q&A sessions, and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited ("Takeda") in connection with this announcement. This press release (including any oral presentations and any questions and answers related thereto) is not intended to and does not constitute, represent or constitute any offer, solicitation or solicitation of any offer to buy, otherwise acquire, subscribe, exchange , sell or otherwise dispose of securities or seek voting or approval in any jurisdiction. This press release does not constitute a public offer of any shares or other securities. No securities may be offered in the United States except by registration or exemption under the US Securities Act of 1933, as amended. This press release (together with any further information that may be provided to the recipient) is provided on the condition that the recipient will use it for informational purposes only (and not to evaluate any investment, acquisition, divestiture or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. Companies in which Takeda has direct and indirect investments are separate entities. In this press release, the term "Takeda" is sometimes used generically to refer to Takeda and its subsidiaries for convenience. Similarly, the terms "we", "our" and "our" are used generally to refer to subsidiaries or persons working for them. These phrases are also used to identify a specific company or situation where it is not useful.

future statement

This press release and any material distributed in connection with this release may contain forward-looking statements, beliefs or opinions regarding Takeda's future business, conditions and results, including Takeda's estimates, projections, goals and plans. Forward-looking statements typically include words such as "objectives," "plans," "believes," "hopes," "continues," "expects," "targets," "intends," "ensures," "will ", "may", "should", "would", "may", "expect", "estimate", "project" or similar expressions or negations thereof. These forward-looking statements are based on assumptions about a number of important factors, including the following factors that could cause actual results to differ materially from those expressed or implied in the forward-looking statements: The economic environment in which Takeda operates worldwide including general economic conditions in Japan and the US Competitive pressures and developments Changes in existing laws and regulations, including global healthcare reforms Challenges inherent in new product development, including uncertainty about clinical success and decisions by regulatory agencies and their deadlines Commercial success difficulties or delays in the production of new and existing products; fluctuations in interest rates and exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises such as the novel coronavirus pandemic on Takeda, its customers and suppliers, including foreign governments in countries where Takeda does business or other aspects of its business; timing and impact of post-merger integration activities with the acquired company; the ability to divest assets that are not critical to Takeda's business and the consequences of any such action timing of the divestiture and other factors identified in Takeda's most recent Annual Report on Form 20-F and other documents filed by Takeda with the SEC, available on Takeda's website at at: / or Takeda undertakes no obligation to update any forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or exchange rules. Past performance is not indicative of future performance, and Takeda's results or statements contained in this press release may not be indicative of, and are not, estimates, projections, guarantees or predictions of Takeda's future performance.

Medical information

This press release contains product information that may not be available in all countries or may be available under a different brand, indication, dosage or strength. Nothing contained herein should be construed as soliciting, promoting or advertising any prescription drug, including drugs under development.

1 Banerji A, Hao J, Ming Y et al. Long-term efficacy and safety of lanadelumab: final results of the open-label HELP extension study. ACAI 2020.
2 Magerl M, Johnston D et al. Seizure-free status on stable lanadelumab treatment in patients with hereditary angioedema: results of the open-label HELP extension study. EAACI 2021.
3 Maurer M, Bernstein J et al. Long-term seizure prophylaxis with lanadelumab in a subgroup of patients with hereditary angioedema (HAE): final results of the open-label HELP extension study. EAACI 2021.
4 Banerji A, Riedl MA, Bernstein JA, and others; For helping the investigators. Effect of lanadelumab versus placebo on preventing episodes of hereditary angioedema: a randomized clinical trial. Journal of the American Medical Association. 2018;320(20):2108-2121.
5 Cicardi M, Bork K, Caballero T, and others on behalf of HAWK (International Working Group on Hereditary Angioedema). Evidence-based recommendations for the treatment of angioedema due to congenital C1 inhibitor deficiency: an international working group consensus report. allergy. 2012;67(2):147-157.
6 Crane BL. Hereditary angioedema. N English J Med. 2008;359(10):1027-1036.
7 Banerji A. Burden of disease in patients with hereditary angioedema. Ann Allergy Asthma Immunization. 2013;111(5):329-336.
8 Longhurst HJ, Bork K. Hereditary angioedema: causes, symptoms and treatment. Br J Hosp Med. 2006;67(12):654-657.
9 Summary of the European Summary of Product Characteristics for TAKHZYRO (lanadelumab).

(Video) 🔴 Al Jazeera English | Live

See source version on


What is the biggest problem in Africa today? ›

One of the most urgent issues confronting the region is the need to tackle decade-high levels of inflation—which are devastating incomes and food security—while also supporting growth. While there are big differences between countries, the median of inflation rates in the region increased to almost 9 percent in August.

What is Africa known for? ›

The continent has 40 percent of the world's gold and up to 90 percent of its chromium and platinum. The largest reserves of cobalt, diamonds, platinum and uranium in the world are in Africa. It holds 65 per cent of the world's arable land and ten percent of the planet's internal renewable fresh water source.

Who is the biggest broadcaster in Africa? ›

SuperSport. SuperSport is Africa's premier sports broadcaster, producing and broadcasting local and international sport for pay-TV subscribers across sub-Saharan Africa.

Why is Africa in crisis? ›

Relentless drought and high food prices have weakened people's ability to grow crops, raise livestock and buy food for their families. Communities in Ethiopia, Kenya and Somalia are facing various compounding crises and the most vulnerable people — refugees and displaced families — are enduring the worst of it.

Why is Africa important to the United States? ›

It has one of the world's fastest growing populations, largest free trade areas, most diverse ecosystems, and one of the largest regional voting groups in the United Nations (UN).

What is the most developed country in Africa? ›

The island country of Mauritius is Africa's most developed country with an HDI of . 802, which just clears the "very high human development" threshold.

What religion is dominant in Africa? ›

Christianity is now one of the most widely practiced religions in Africa along with Islam and is the largest religion in Sub-Saharan Africa. Several syncretistic and messianic sects have formed throughout much of the continent, including the Nazareth Baptist Church in South Africa and the Aladura churches in Nigeria.

What was the original name of Africa? ›

In Kemetic History of Afrika, Dr cheikh Anah Diop writes, “The ancient name of Africa was Alkebulan. Alkebu-lan “mother of mankind” or “garden of Eden”.” Alkebulan is the oldest and the only word of indigenous origin. It was used by the Moors, Nubians, Numidians, Khart-Haddans (Carthagenians), and Ethiopians.

Why is it called Africa? ›

The origin of the name “Africa” is greatly disputed by scholars. Most believe it stems from words used by the Phoenicians, Greeks, and Romans. Important words include the Egyptian word Afru-ika, meaning “Motherland”; the Greek word aphrike, meaning “without cold”; and the Latin word aprica, meaning “sunny.”

Which media is most popular in Africa? ›

Facebook is the leading social media platform in Africa in terms of market share.

What is the most watched TV channel in Africa? ›

Tanzania Audience Share:
  • ITV: 25.66%
  • EATV: 23.96%
  • Clouds: 16.44%
  • Star: 14.24%
  • Channel 10: 8.24%
  • BBC: 6.35%
Jun 6, 2014

What is the most watched news channel in Africa? ›

A survey conducted between January and February 2022 in South Africa concluded SABC News had the highest weekly reach among TV, radio, and print media in the country.

Why is Africa a very poor country? ›

Bad governance, corruption and high-income inequality also drive up poverty. Africa's high fertility rates mean that economic growth rates translate into smaller per capita income increases. While the extreme poverty rate will likely fall, the number of poor people will rise due to Africa's high population growth rate.

Does the US send food to Africa? ›

As of August 8, 2022, the U.S. has provided nearly $1 billion specifically for countries in Africa toward this $2 billion commitment, including Central African Republic, the Democratic Republic of the Congo, Ethiopia, Kenya, Mali, Mozambique, Nigeria, Somalia, South Sudan, and Uganda.

Why can't Africa grow food? ›

So what then is the real reason? It's pretty simple: African farmers are, on average, the poorest and least educated in the world. They have the least ability to afford irrigation, farm equipment, fertilisers, quality seeds, cutting-edge knowledge, and the other inputs that make for productive agriculture.

What US state is closest to Africa? ›

Of all U.S. states, the one closest to Africa is Maine.

Has America ever helped Africa? ›

The United States is the largest donor of humanitarian assistance to Africa, leading the international community to support African countries with a range of bold new commitments that bolster life-saving humanitarian aid to the most vulnerable communities.

What has USA done for Africa? ›

Since 2021, the U.S. Government has helped close more than 800 two-way trade and investment deals across 47 African countries for a total estimated value of over $18 billion, and the U.S. private sector has closed investment deals in Africa valued at $8.6 billion.

What is the safest country in Africa? ›

Top 5 Safest Countries in Africa
  • Mauritius. According to the GPI, Mauritius is the safest country in Africa. ...
  • Ghana. Ghana is the second safest country in Africa, according to the GPI. ...
  • The Gambia. ...
  • Botswana. ...
  • Sierra Leone. ...
  • Sudan. ...
  • Central African Republic. ...
  • Somalia.
Dec 28, 2022

What is the poorest country in Africa? ›

Western Sahara is the poorest country in Africa, with a GNI per capita of $56. Burundi is the second poorest in Africa, with a GNI per capita of $220. Somalia, the third poorest African country, has a GNI per capita of $430. The Central African Republic, which ranks fourth, has a GNI per capita of $480.

Who is the richest man in Africa? ›

1. ALIKO DANGOTE. * Aliko Dangote, Africa's richest person, founded and chairs Dangote Cement, the continent's largest cement producer. * He owns 85% of publicly-traded Dangote Cement through a holding company.

What will Africa look like in 2050? ›

The populations of more than half of Africa's 54 nations will double – or more – by 2050, the product of sustained high fertility and improving mortality rates. The continent will then be home to at least 25% of the world's population, compared with less than 10% in 1950.

How many years will it take for Africa to split? ›

While the splitting of the African continent and the subsequent ocean that would arise holds an abundance of possibilities, the continent will not completely split for another 5 to 10 million years, according to researchers.

Where is the biggest crack in the Earth? ›

▲According to the scholar, the Great Rift Valley in East Africa is an area which extends over 1,860 mi (3,000 km), from north to south between the Gulf of Aden, near Somalia, and Zimbabwe.

What did African worship before Christianity? ›

Forms of polytheism was widespread in most of ancient African and other regions of the world, before the introduction of Islam, Christianity, and Judaism. An exception was the short-lived monotheistic religion created by Pharaoh Akhenaten, who made it mandatory to pray to his personal god Aten (see Atenism).

What is the most spoken language in Africa? ›

The most widely spoken languages of Africa, Swahili (200 million), Yoruba (45 million), Igbo (30 million), and Fula (35 million) all belong to the Niger-Congo family.

What is the fastest growing religion in the United States? ›

According to various scholars and sources Pentecostalism – a Protestant Christian movement – is the fastest growing religion in the world, this growth is primarily due to religious conversion. According to Pulitzer Center 35,000 people become Pentecostal or "Born again" every day.

What do most Africans do for a living? ›

70% of Africans make a living through agriculture, and technology could transform their world | World Economic Forum.

What meat do Africans eat? ›

Beef and chicken are favorite meat dishes, but game meat preparations containing crocodile, elephant, antelope and warthog are also served occasionally.

What is Africa called in the Bible? ›

Cush, Cushitic and Cushi

In the Major Prophets, the terms used to refer to Africa and Africans appear more than 180 times. Cush appears also as a geographical location.

Is the garden of Eden in Africa? ›

The real Garden Of Eden has been traced to the African nation of Botswana, according to a major study of DNA. Scientists believe our ancestral homeland is south of the Zambezi River in the country's north.

Who came first in Africa? ›

Portuguese explorer Prince Henry, known as the Navigator, was the first European to methodically explore Africa and the oceanic route to the Indies. From his residence in the Algarve region of southern Portugal, he directed successive expeditions to circumnavigate Africa and reach India.

Why is Africa called dark? ›

Africa was called the dark continent because of the obstacles encountered while attempting to explore its interior. The plateau rim of the continent extends to the coast and in the north, the Sahara Desert was a formidable obstacle to reach the interior.

What is the oldest ethnicity in the world? ›

A new genomic study has revealed that Aboriginal Australians are the oldest known civilization on Earth, with ancestries stretching back roughly 75,000 years.

What did the Romans call Africa? ›

The name Africa came into Western use through the Romans, who used the name Africa terra — "land of the Afri" (plural, or "Afer" singular) — for the northern part of the continent, as the province of Africa with its capital Carthage, corresponding to modern-day Tunisia.

Which country uses internet the most in Africa? ›

With a penetration rate of 51% per cent of the total population of the country, Nigeria is one of the leading countries with the highest number of Internet users. Egypt ranks second in the number of Internet users.

Which country uses Facebook the most in Africa? ›

By April 2022, Nigeria was the country in West Africa with the largest number of Facebook subscribers. About 31.8 million users in Nigeria had a Facebook account.

What music is listened to in Africa? ›

Most contemporary genres of African popular music build on cross-pollination with Western popular music. Many genres of popular music like blues, jazz, afrobeats, salsa, zouk, and rumba derive to varying degrees on musical traditions from Africa, taken to the Americas by enslaved Africans.

What is the most televised thing in the world? ›

Most-watched broadcasts of all time (total viewers)
1Death and state funeral of Elizabeth II2022
2Wedding of Prince Charles and Lady Diana Spencer1981
32000 Summer Olympics closing ceremony2000
42000 Summer Olympics opening ceremony2000
6 more rows

Which country watches the most TV? ›

Wideangle: Which countries watch the most TV?
  • CROATIA: 85% ...
  • POLAND: 84% ...
  • IRELAND: 81% ...
  • FRANCE: 73% ...
  • GERMANY: 70% ...
  • SWEDEN: 60%
Mar 16, 2023

What is the most watched news media in the US? ›

As some of the most widely available channels, Fox News, CNN, and MSNBC are often referred to as the "big three" with Fox News having the highest viewership and ratings.

Who controls the Africa Channel? ›

The Africa Channel is a cable and streaming channel focusing on travel, lifestyle, and culture documentaries. The channel covers the lands, people, culture, and history of Africa. Co-founded by Zimbabwean James Makawa, the Africa Channel launched in the United States in September 2005.

Is there conflict in Africa today? ›

Despite this progress, crises and conflicts persist in Africa, affecting the daily lives of its people, he said, expressing concern over violent extremism, terrorism and the proliferation of small arms and light weapons.

What are the issues in Africa in the 21st century? ›

pandemic, which has significantly reduced the region's economic growth potential. Social scientists have been grappling with problems including climate change and agricultural productivity, livelihoods and wellbeing, youth unemployment, increasing crime and violence, weak institutions and poor governance.

What is the richest country in Africa? ›

Seychelles is the richest country in Africa, with a GNI per capita of $14,540. Mauritius follows closely with a GNI per capita of $9,920, while Libya is the third richest country in Africa with a GNI per capita of $8,700. South Africa is the fourth richest country in Africa with a GNI per capita of $6,530.

Which country in Africa has the best environment? ›

Recommended articles
RankCountryATB Score
1.South Africa100.00
6 more rows
May 8, 2023

What country in Africa is most vulnerable to climate change? ›

  • CHAD. It is considered the most vulnerable country on the planet according to the University of Notre Dame's country vulnerability studies, ...
  • SOMALIA. ...

Which country is fighting in Africa? ›

The armed conflicts in Burkina Faso, Cameroon, Chad, Mali, Niger and Nigeria all worsened in 2019. The security challenges are linked to the rise of violent extremism and the proliferation of armed non-state groups, such as Boko Haram, which has spread from Nigeria across the Lake Chad region.

Why are there so many wars in Africa? ›

Understanding the Causes of Conflicts in Africa

Africa has a high prevalence of civil wars and this is commonly attributed to the ethnic diversity of its countries. This inference seems self-evident to many, given that African rebel movements almost always are ethnically defined.

What wars is the US in right now? ›

Who is America at war with right now?
CountryDates of Conflict
Afghanistan2001 – present
Iraq2003 – 2011, 2014 – present
Syria2014 – present
Somalia2001 – present
1 more row
Mar 9, 2023

What are 3 of the main problems in Africa? ›

Intra-state conflict, terrorism, and unconstitutional changes of government are three of the biggest security issues in Africa to monitor in 2022.

What causes terrorism in Africa? ›

Despair, poverty, hunger, lack of basic services, unemployment, and unconstitutional changes in Government continue to lay fertile ground for the expansion of terrorist groups across the continent.

How many people are hungry in Africa? ›

Today a fifth of the African population (278m) is undernourished, and 55 million of its children under the age of five are stunted due to severe malnutrition. “The hunger African people are facing today is a direct result of inadequate political choices.


1. #SABCNews Headlines @06H30 | 31 May 2023
(SABC News)
2. Approximately 178 000 Zimbabweans living in SA face possible deportation at the end of next month
(SABC News)
3. South Africa opposition makes legal bid to force Putin's arrest at BRICS summit • FRANCE 24
(FRANCE 24 English)
4. An inside look at the Wagner Group’s control over the Central African Republic
(NBC News)
5. South Africa Grants Vladimir Putin Immunity for BRICS Summit | Vantage on Firstpost
6. U.S Accuses South Africa Of Supplying Arms To Russia
(African Diaspora News Channel)


Top Articles
Latest Posts
Article information

Author: Kimberely Baumbach CPA

Last Updated: 08/30/2023

Views: 6322

Rating: 4 / 5 (41 voted)

Reviews: 88% of readers found this page helpful

Author information

Name: Kimberely Baumbach CPA

Birthday: 1996-01-14

Address: 8381 Boyce Course, Imeldachester, ND 74681

Phone: +3571286597580

Job: Product Banking Analyst

Hobby: Cosplaying, Inline skating, Amateur radio, Baton twirling, Mountaineering, Flying, Archery

Introduction: My name is Kimberely Baumbach CPA, I am a gorgeous, bright, charming, encouraging, zealous, lively, good person who loves writing and wants to share my knowledge and understanding with you.